Body weight-adjusted oral rivaroxaban is a possible treatment option for pediatric patients with venous thromboembolism (VTE), according to the EINSTEIN-Jr. study presented at the 2019 ASH Annual Meeting. EINSTEIN-Jr. is a comprehensive clinical development program that seeks to provide data to support the use of rivaroxaban for children with VTE. Previous results from the phase III EINSTEIN-Jr. study showed similar safety and efficacy between rivaroxaban and standard anticoagulation for pediatric VTE. Updated results from the trial assessed the ...
ASH Annual Meeting 2019 Conference Coverage
Advertisement
Results from the COLUMBA study were presented at the 2019 ASH Annual Meeting.
Frailty can adversely affect the outcomes of allogeneic hematopoietic cell transplantation (alloHCT).
A global study observed an increased trend in autologous hematopoietic cell transplantation among patients with MM.
The results were presented at the 2019 ASH Annual Meeting.
Peter M. Voorhees, MD, discussed B-cell maturation antigen (BCMA)-targeted CAR T-cell treatment strategies.
The Pleiades study assessed subcutaneous (SC) versus intravenous (IV) administration of daratumumab.
CD123 expression is strongly correlated with disease-relevant cytogenetic and molecular alterations in AML.
The analysis identified 505,230 admissions in 2014.
Advertisement
